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Multiple Endocrine Neoplasia Type 2 (MEN2) are autosomal domi-
nant hereditary diseases, related to mutations of the RET (REarranged
during Transfection) proto-oncogene (Donis-Keller et al., 1993).
MEN2A is a rare syndrome which associates medullary thyroid cancer
(MTC), pheochromocytoma, hyperparathyroidism, cutaneous lichen
amyloidosis, and Hirschsprung disease in some patients (Wells et al.,
2013). It affects therefore organs originating fromendodermal and ecto-
dermal layers. Mouse models have been unsuccessful in recapitulating
the full clinical spectrum of MEN2A (Michiels et al., 1997). The most
common mutation, accounting for over 80% of all mutations associated
with the classic MEN2A, affects codon 634 (Wells et al., 2013). Muta-
tions at codon 634 are classiﬁed as high risk, according to the American
Thyroid Association (ATA) guidelines (Wells et al., 2015). In this work
we sought to determine the feasibility of modelling the MTC from a pa-
tient with the germline RET mutation who developed this tumor in the
context of familial cancer. This patient was a 28-year oldmanwithMTC
and pheochromocytoma. Themother of the patient had undergone sur-
gery for MTC 20 years previously.
Cryopreseved peripheral blood mononuclear cells (PBMCs) from
this patient were used for the generation of an induced pluripotent
stem cell (iPSC) that harbour a “high risk” RET mutation according to
ATA guidelines, i.e. a 1901G N A missense mutation leading to the
most frequent C634Y amino acid substitution seen in Ret in MEN2A.
iPSCs were generated by non-integrative transduction of Oct3/4, Sox2,
Klf4, and cMyc (Takahashi et al., 2007). They expanded as typical iPSC
colonies on eithermouse embryonic ﬁbroblast feeders (MEF) or in feed-
er-free conditions (Fig. 1A). Cytogenetics analysis was normal (Fig. 1B).
These iPSCs exhibited typical markers of pluripotency with as expres-
sion of SSEA3, SSEA4 and TRA-1-60 (Fig. 1B). Cells also expressed Oct-
4 at a high level (Fig. 1C). The 1901G N A missense mutation was con-
ﬁrmed at both genomic (Fig. 1D) and cDNA levels. RET expression on
iPSC was demonstrated by FACS analysis using a phospho-RET antibody
(Fig. 1E). A teratoma assaywas performed to further conﬁrm the plurip-
otent nature of the RET-mutated iPSC.
2. Materials and methods
2.1. Human iPS cell generation and culture
4 days before reprogramming, peripheral blood mononuclear cells
(PBMCs) were thawed, cultured and expanded in Myelocult™medium
(Stemcell Technologies) supplementedwith 1% penicillin-streptomycin
(Life technologies), hSCF 100 ng/mL, hFLT-3100 ng/mL, hIL-3 20 ng/mL,
hIL-6 20ng/mL, and hIL7 20 ng/mL (all of them fromPeprotech). 2 × 105
PBMC were then transduced overnight with Sendai viruses containing
Oct3/4, Sox2, Klf4, and cMyc (CytoTune®-iPS Sendai Reprogramming
Kit, Life technologies) each of them at multiplicity of infection (MOI)
of 15. The next 2 days, mediumwas changed daily and cells were resus-
pended in expansion medium after 5 min centrifugation at 200 ×g. The
third day, cells were recovered by centrifugation and plated onMitomy-
cin-C-treated mouse embryonic ﬁbroblasts (MEF, CD1 strain) in expan-
sion medium for 2 additional days. At day 6, half of the medium was
changed to human pluripotent stem cell medium (hPSC medium)
based on DMEM/F12 supplemented with 20% Knock Out Serum
Replacer, 1 mM L-glutamine, 1% penicillin/streptomycin, 100 μM 2-
mercaptoethanol (all of them from Life technologies) and 12.5 ng/mL
basic FGF (Miltenyi Biotech). Then, the medium was changed daily
with hPSCmedium. At day 26, fully reprogrammed colonies were man-
ually picked and transferred to freshly Mitomycin-C-treated MEF for
ampliﬁcation.
iPSC culture was performed according to two different procedures:
in the presence of feeders or in feeder-free conditions. The feeder cul-
tures were performed on Mitomycin C-treated MEF layer as described
above with passaging every 7 days using 1 mg/mL collagenase IV inDMEM/F12 (Life technologies)); the feeder-free culture was performed
on Geltrex™ (Life technologies) in Essential 8 medium (Life technolo-
gies) and 1% penicillin/streptomycin with passaging every 3–4 days
using in DPBS (Life technologies) supplemented with 0.5 mM EDTA
(Life technologies) and 1.8 mg/L NaCl (Sigma).
2.2. Karyotyping and mutation analysis
For conventional cytogenetics, cells grown in 60 mm plates
(Corning) on Mitomycin-C treated MEF for 5 days were cultured 2 h
in hPSC medium supplemented with 100 ng/mL Colcemid™ (Life tech-
nologies). Cells were detached from the plate by 5 min treatment with
1 mL per plate of TrypLE™ Express (Life technologies) at 37 °C, 5%
CO2. After trituration with a P1000 micropipet, 9 mL of 0.075 M KCl
(Life technologies) was added to the cell suspension followed by incu-
bation at 37 °C during 20 min to obtain an osmotic shock. Cell suspen-
sion was then preﬁxed by the addition of 1 mL of ﬁxative composed of
Methanol/Acetic Acid (3:1) followed by 10 min centrifugation at
130 ×g. Cell pellet was then resuspended in 10 mL of ﬁxative and cen-
trifuged 10 min at 130 ×g two times before a ﬁnal resuspension in
10 mL of ﬁxative. Cells were then spread on slides and stained with
Giemsa. A minimum of 10 metaphases were captured and analysed
using an automated imaging system (Meta Systems).
Genomic DNA from iPSC was extracted with DNeasy blood & Tissue
kit (Ref 69504, Qiagen) according to the manufacturer instruction.
Human Genomic DNA was used as control (Roche). RET exon 11 and
surrounding intronic regions were PCR ampliﬁed with high-ﬁdelity
PCR polymerase (Herculase II fusion DNA polymerase, Agilent) using
the following cycling parameter: 2 min of denaturation at 95 °C follow-
ed by 30 cycles with 10 s at 95 °C, 20 s at 55 °C and 30 °C at 72 °C and a
ﬁnal 3 min elongation step at 72 °C. Primers forward 5′-GCCAGCTGGTG
TAATGAGCA-3′ and reverse 5′-ACCGTTCACTCACACCCTTG-3′ were
used, leading to a 1058 bp amplicon (NC_000010.11, 43114189–
43115246). This PCR product was then puriﬁed with exo SAP mix
(0.5 μL Exonuclease I, Eurobio and 2 μL Shrimp Alkaline Phosphatase,
Ozyme) incubation (15min at 37 °C and then 15min at 80 °C) associat-
ed with BigDye Xterminator kit used according to the manufacturer in-
struction (Applied Biosystems). Puriﬁed product was then subjected to
sequencing reaction with BidDye Terminator kit (Applied biosystem):
denaturation 5 min at 95 °C followed by 25 cycles with 10 s at 95 °C,
5 s at 50 °C and 4 min at 60 °C using either RET634_seq forward 5′-
CAGAGCATACGCAGCCTGTA-3′ RET_seq reverse 5′-CTCCGGAAGGTC
ATCTCAGC-3′ primers.
2.3. Pluripotency markers and ret expression
For ﬂow cytometry analysis, iPSC colonies were recovered from Mi-
tomycin-C inactivated MEF after incubation for 2 h in 1 mg/mL collage-
nase IV in DMEM/F12. After two cycles of washing/sedimentation with
10 mL DMEM/F12, colonies were washed once in Ca2+/Mg2+ free
PBS (Life technologies) and then dissociated into a single cell suspen-
sion by 10 min incubation in Hank's balanced enzyme-free cell dissoci-
ation buffer (Life Technologies). For pluripotency marker analysis,
1 × 105 cells were incubated in 10 μL PBS containing 1 μL Phycoery-
thrin-conjugated rat monoclonal antibody anti-SSEA3, 1 μL V450-
conjugated mouse monoclonal anti-SSEA-4 and 1 μL Alexa647-
conjugated mouse monoclonal antibody anti-TRA1-60 (all of them
from BD Biosciences) or conjugated isotype control. For Ret expression
analysis, 1 × 105 cells were incubated in 10 μL PBS containing 1 μL
APC-conjugated mouse monoclonal antibody anti-Ret (R&D) or conju-
gated isotype control. Cells were analysed with a MACSQuant
ﬂowcytometer using the MACSQuantify software.
Immunostaining were also performed on colonies cultured in 8
wells Lab-Tek™ chambers (Nunc). Brieﬂy, cells were ﬁxed 20 min at
room temperature in 4% paraformaldehyde in PBS and rinsed twice
times with PBS. Cells were then permeabilized 5 min in 0.25% Triton-
Fig. 1. Characterization of the RETC634Y PB48 iPSC line A: Phase contrast imaging of PB48 colonies grown onmatrigel (×4) and cytogenetics analysis of iPSC revealing a normal karyotype. B: FACS evaluation of pluripotencymarkers using SSEA3, SSEA4
and TRA-1-60 staining. C: Immunoﬂuorescence analysis of Oct4 and TRA-1-60 expression (×20) D: C634Ymutation identiﬁed by Sanger sequencing in PB48 iPSC. E: RET expression in PB48 iPSC by ﬂow cytometry using a phosphor-RET antibody. F:
Pathological analysis of teratoma from PB48 iPS, showing a normal ectodermal, endodermal and mesodermal differentiation.
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157J. Hadoux et al. / Stem Cell Research 17 (2016) 154–157X100 (Sigma) in PBS and then rinsed twice in PBS. Wells were stained
45min at room temperature in 100 μL PBS containing 1 μL ratmonoclo-
nal antibody anti-Tra160 (Millipore) and 1 μL rabbit polyclonal antibody
anti-Oct-4 (Millipore) or 1 μL of each irrelevant isotype controls. After
two washes in PBS, cells were stained 45 min at room temperature in
100 μL PBS containing 0.2 μL Alexa488 conjugated goat anti-rabbit anti-
body and 0.2 μL Alexa594 conjugated goat anti-mouse IgM antibody
(both from Life technologies). Wells were washed twice in PBS and
mounted in Dapi containing mounting medium (Vector Laboratories)
before analysis on a Nikon 90i ﬂuorescent microscope.
2.4. In vivo pluripotency analysis by teratoma formation
MEN2A-iPSCs were subjected to teratoma formation assay by intra-
muscular injection of NSG mice (2 · 106 cells in 150 μL of Geltrex/
DMEMEF12 1:1 dilution) and pathological analysis after 8 to 10 weeks
of tumour growth. Teratoma formation assays were performed in tripli-
cate in order to analyse thedevelopment of potentiallymalignant tumor
tissue within teratomas. At +2 months after injections, RET-mutated
iPSC gave rise to teratomas, thus conﬁrming the pluripotency of these
cells (Fig. 1D). Pathological analyses showed the presence of a normal
endodermal, ectodermal and mesodermal differentiation with no ma-
lignant tissue identiﬁed in several teratomas analysed (Fig. 1F).Acknowledgements
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